Harnessing human tumor organoids for cancer modeling and precision therapy
Protein & Cell · 2026
DOI: 10.1093/procel/pwag007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Protein & Cell, 2026. Verfasst von Tonghai Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy…. Hauptthemen laut MEDLINE: Organoids, Neoplasms, Precision Medicine, Models, Biological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 260 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Human tumor organoids represent a paradigm shift in cancer modeling, overcoming critical limitations of conventional systems by faithfully recapitulating genetic heterogeneity, three-dimensional architecture, and tumor microenvironment dynamics of patient tumors. Our review explores how human tumor organoids serve as a transformative preclinical platform, bridging the gap between basic research and clinical translations. We highlight recent advances in tumor organoid generation, spanning patient-derived organoids to genetically engineered platforms from normal tissue and human pluripotent stem cells, and their applications in deciphering carcinogenesis, clonal evolution, and metastatic mechanisms. We further examine technological innovations in culture systems that enhance the interpretability and translatability of tumor phenotypes and drug responses. We present an in-depth exploration of how integrated tumor microenvironment co-culture systems—combining immune cells, cancer-associated fibroblasts, and vascular components–enable novel investigations into tumor-stroma-immune crosstalk. Clinically, human tumor organoid biobanks have shown great promise in predicting personalized therapy responses. Emerging technologies like organoids-on-chip platforms, three-dimensionally bioprinting and artificial intelligence-driven analytics are enhancing high-throughput drug screening efficiency and biomarker identification. Despite advances, complete microenvironmental modeling remains challenging, particularly in replicating vascular complexity and systemic immune responses. Future advancements will demand convergence of synthetic biology, functional genomics, and machine learning to transform human tumor organoids from static avatars into dynamic “living biosensors”. In summary, this review provides an in-depth exploration of the organoid field and presents a clear and actionable framework for positioning tumor organoids as indispensable tools in functional precision medicine—a strategy that ultimately bridges mechanistic discoveries with clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, C…
- McKusick-Zhang Center for Genetic Medicine, Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100…
ORCID-Profile: Tonghai Zhou, Qianyi Wang, Meili Zhang, Yue Huang
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Zhou, T., Wang, Q., Zhang, M., & Huang, Y. (2026). Harnessing human tumor organoids for cancer modeling and precision therapy. Protein & Cell. https://doi.org/10.1093/procel/pwag007
Vancouver
Zhou T, Wang Q, Zhang M, Huang Y. Harnessing human tumor organoids for cancer modeling and precision therapy. Protein & Cell. 2026. doi:10.1093/procel/pwag007
BibTeX
@article{Zhou2026,
author = {Zhou, Tonghai and Wang, Qianyi and Zhang, Meili and Huang, Yue},
title = {Harnessing human tumor organoids for cancer modeling and precision therapy},
journal = {Protein & Cell},
year = {2026},
doi = {10.1093/procel/pwag007}
}
EUVIMED